Angiogenesis inhibitors: current strategies and future prospects. - Wikidata - awgldk - TriplyDB

Angiogenesis inhibitors: current strategies and future prospects.

Angiogenesis inhibitors: current strategies and future prospects.

http://www.wikidata.org/entity/Q34056376

about

Crystal structures of the catalytic domain of human soluble guanylate cyclase Biophytum sensitivum: Ancient medicine, modern targets Melatonin and Other Tryptophan Metabolites Produced by Yeasts: Implications in Cardiovascular and Neurodegenerative Diseases Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment Myeloid Cells as Targets for Therapy in Solid Tumors NMR structure and dynamics of recombinant wild type and mutated jerdostatin, a selective inhibitor of integrin α1β1 Biomarkers Discovery for Colorectal Cancer: A Review on Tumor Endothelial Markers as Perspective Candidates Adaptation to antiangiogenic therapy in neurological tumors JSI-124 suppresses invasion and angiogenesis of glioblastoma cells in vitro Selective depletion of tumor neovasculature by microbubble destruction with appropriate ultrasound pressure Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression.A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome VEGF sticky-trap: the first report of a non-systemically acting angiogenesis inhibitor.A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling.Increased expression of CYP4Z1 promotes tumor angiogenesis and growth in human breast cancer.Nitidine chloride inhibits hepatic cancer growth via modulation of multiple signaling pathways Exploring the role of mitochondrial UQCRB in angiogenesis using small molecules.A novel poly-naphthol compound ST104P suppresses angiogenesis by attenuating matrix metalloproteinase-2 expression in endothelial cells.Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells.A phase II study of conventional radiation therapy and thalidomide for supratentorial, newly-diagnosed glioblastoma (RTOG 9806).Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects Anti-angiogenic activities of two recombinant disintegrins derived from the Mohave and Prairie rattlesnakes.Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy.1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice In vitro 3D angiogenesis assay in egg white matrix: comparison to Matrigel, compatibility to various species, and suitability for drug testing.Cancer cell invasion: treatment and monitoring opportunities in nanomedicine.Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies.Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.Antiangiogenic activity of the lipophilic antimicrobial peptides from an endophytic bacterial strain isolated from red pepper leaf.Lonafarnib is a potential inhibitor for neovascularization.Multitarget inhibitors derived from crosstalk mechanism involving VEGFR2.Toward a Cancer Drug of Fungal Origin Angiogenesis dependent characteristics of tumor observed on rabbit VX2 hepatic carcinoma.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Cabozantinib, a Novel c-Met Inhibitor, Inhibits Colorectal Cancer Development in a Xenograft Model.Discovery of Novel Antiangiogenic Marine Natural Product Scaffolds.An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.

P2860

Q24336722-B8D28C59-26AE-451D-860A-976207D4884C Q24630506-79D8FCD5-D9B7-42D5-94DC-9B5C477D47B9 Q26772733-788977A1-DB15-4B87-A81A-9E24FEE9DE2F Q26799914-57741DEF-DFAD-44E5-8C60-D12BC67E8855 Q26801832-1977A8CE-C04F-4C31-9FB0-1F3AD893C9BD Q27668187-35E62F59-1B18-4071-AB2C-E5FF3DEB33CC Q28071510-97A65208-B9CC-4A48-966C-FFC5FE0EE992 Q28082908-3692CECB-E696-4C2B-9B73-98B87886F72F Q28544728-676F85EA-762E-4EB5-9D34-A0B060BADFFD Q30356174-0F9C1EC3-D9F5-419E-91AB-9B83E95FD7D0 Q30448565-0E4F6F11-D358-40C7-9B2D-1D86897968C9 Q33418285-0C1DB746-C661-47E4-8D5F-B9D059CF1411 Q33623339-017021D4-B39C-440F-B58F-BE8805B600BE Q33889409-FD6EC87B-5436-4BC9-B44E-D60BF322CABC Q33960155-B101063C-E2FC-41AE-B143-5DC56692F590 Q34238619-C6551607-C16D-43E1-885F-A455CD5CD8DE Q34290867-A7349DF8-2B0C-4E33-89A8-1ACEF03EC371 Q34309479-3E400895-9333-4409-9E3E-93D220C448FF Q34332044-9F26C937-938B-4803-93EF-F16CC770ADB6 Q34358400-729A0B81-9F6E-43FC-ABFF-3E00EE916C9D Q34362205-F7B80926-4A66-4413-86EC-80FAC7A8C577 Q34453644-98F7EA47-C7AE-49B6-9038-6555548FD28D Q34670026-5DBEC31D-8D22-4E24-8FA6-9FAB121BDA19 Q34730272-257B15C2-4A6D-4EE1-A5D5-596D540CB118 Q34984769-8767AFF8-F396-4E9F-B0C6-89F9F2FDADFA Q35020469-25215AAA-68B0-40C5-8374-3A269FECB8C8 Q35078276-88CFAC63-DB64-4FB1-BEB9-D7720A53F809 Q35084122-8764BB32-DEFD-43D2-B7D1-73BB63C70ABE Q35093966-8D07B723-332A-4C1E-A614-E64DD9800C3A Q35113402-483E20F8-63AB-40CD-AD33-E22F9DF0EA8F Q35177682-7757BFCB-D228-4EEE-98EB-C1DCF51794A4 Q35188518-F58DAE2B-1B54-4DDC-8973-0EB58854A3F5 Q35324064-17129EE0-94AC-4E97-8CED-09BD36A5DCE9 Q35434188-AD25800E-EA2A-4902-812A-BA2201BB6969 Q35596957-5FBA8F76-8A4E-401E-B166-3C8B730C73CE Q35882982-70E4497D-E9F3-4B83-B1E2-F1A223A858A1 Q35954103-8C688E87-D40B-493E-9B64-31DC544D6EAC Q35954738-CEDC2FAD-63C2-422C-915D-D469C2F38CCB Q35957698-D6D7951C-2507-4FD9-A814-C2101AA98165 Q35996229-25E412C3-5423-4A87-997A-EE7F01D926B1

P2860

Angiogenesis inhibitors: current strategies and future prospects.

http://www.wikidata.org/entity/Q34056376

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Angiogenesis inhibitors: current strategies and future prospects.

@ast

Angiogenesis inhibitors: current strategies and future prospects.

@en

Angiogenesis inhibitors: current strategies and future prospects.

@nl

type

label

Angiogenesis inhibitors: current strategies and future prospects.

@ast

Angiogenesis inhibitors: current strategies and future prospects.

@en

Angiogenesis inhibitors: current strategies and future prospects.

@nl

prefLabel

Angiogenesis inhibitors: current strategies and future prospects.

@ast

Angiogenesis inhibitors: current strategies and future prospects.

@en

Angiogenesis inhibitors: current strategies and future prospects.

@nl

P1433

Q34056376-BD182AEA-BBC3-4DED-BA5E-A81FA3E781D3

P1476

Q34056376-C7DBD682-E2E5-4BF1-985B-CDF64F13E8C0

P2093

Q34056376-060DBE53-5BF7-4563-912C-55E581EF1FDE

Q34056376-A2D05DED-1010-45DE-A48D-D3389C7F0669

P2860

Q34056376-0233474F-774B-4162-A3B5-A862609F72A3

Q34056376-04BBD2F1-FEFC-4526-AB0F-7674C1119EA9

Q34056376-054BA70F-739A-4789-8945-525F9E03B746

Q34056376-07818816-738E-47CD-8D8E-E8F7882A622F

Q34056376-0989AFEE-6259-442B-B3C2-4658CDEF8B75

Q34056376-0B3D60F4-BDB8-49F1-9460-5A5F93BB35A4

Q34056376-0B7BD8C6-206E-45D4-9B23-A2E32D6BE443

Q34056376-0C2A88A7-AF92-482D-A9EE-AE792D332827

Q34056376-0D735C70-4223-4175-BD35-008EE7E0C590

Q34056376-0E2BBF97-D585-464A-83C3-179F0642C3B9

P304

Q34056376-35D04FA5-EE04-42EE-B4D1-1DC748C870AF

P31

Q34056376-ED8D94C4-69FA-47B4-AC52-6E417F9A3043

P356

Q34056376-E10C065B-3104-43D2-A800-E2586E2C4176

P407

Q34056376-8CA66142-46FC-434E-984E-9F9E662FD7B1

P433

Q34056376-7DD1AFAB-4228-48F9-9162-911518C63FDB

P478

Q34056376-9DEA445E-71BD-48C9-8C70-07BB8ACB4233

P577

Q34056376-5DF55D6B-5A38-4759-A116-AD31C347F0B1

P5875

Q34056376-E82F2C85-C4C4-4494-B50A-B31779A52932

P698

Q34056376-3B986604-17AC-427E-A1C0-103BC9EC702E

P932

Q34056376-EAB0F8A9-2C89-43B4-98AB-1E6ACEE2C0BD

P356

P1433

P1476

Angiogenesis inhibitors: current strategies and future prospects.

@en

P2093

Kristina M Cook

http://www.w3.org/2001/XMLSchema#string

William D Figg

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

Thalidomide is an inhibitor of angiogenesis

An orally delivered small-molecule formulation with antiangiogenic and anticancer activity

Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2

The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

P304

222-243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3322/CAAC.20075

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228004710

http://www.w3.org/2001/XMLSchema#string

P698

20554717

http://www.w3.org/2001/XMLSchema#string

P932

2919227

http://www.w3.org/2001/XMLSchema#string